Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Fsd Pharma Inc Cl B
(NQ:
HUGE
)
0.1383
-0.0045 (-3.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fsd Pharma Inc Cl B
< Previous
1
2
3
4
5
6
7
8
Next >
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M
February 25, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000
February 25, 2022
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Unveils Newly Designed Website
January 20, 2022
Via
Investor Brand Network
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Unveils Newly Designed Corporate Website
January 20, 2022
Via
Investor Brand Network
FSD Pharma Announces Launch of New Corporate Website
January 20, 2022
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Board Member Named to the Order of Canada
January 18, 2022
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Member Named to the Order of Canada
January 18, 2022
Via
Investor Brand Network
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada
January 18, 2022
From
FSD Pharma Inc.
Via
Business Wire
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference
January 04, 2022
Via
Investor Brand Network
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
January 04, 2022
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
December 30, 2021
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
December 30, 2021
Via
Investor Brand Network
FSD Pharma Announces Share Repurchase Program
December 30, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating MS
December 23, 2021
Via
Investor Brand Network
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Announces Establishment of Advisory Board, Strategic Appointments
December 23, 2021
Via
Investor Brand Network
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
December 09, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
December 03, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
December 02, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
November 16, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
October 19, 2021
From
FSD Pharma Inc.
Via
Business Wire
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...
Via
FinancialNewsMedia
Exposures
Product Safety
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
September 22, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
September 21, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
August 25, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial
August 24, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause
July 27, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Inc. Appoints a New Independent Director
June 03, 2021
From
FSD Pharma Inc.
Via
Business Wire
KILL FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer
May 26, 2021
Via
Business Wire
FSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders – Nominees of the Concerned Shareholders Elected to the Board of Directors
May 17, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer
May 13, 2021
From
FSD Pharma Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.